Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Saturday, September 27th. Finally, Craig Hallum initiated coverage on shares of Adaptive Biotechnologies in a research report on Wednesday, June 18th. As a group, analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current fiscal year. Adaptive Biotechnologies Company Profile(Get Free Report)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Featured StoriesReceive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.